Rat CD80 / B7-1 Protein (Fc Tag, ECD)

Catalog Number: 80027-R02H



General Information

Gene Name Synonym:

CD80

Protein Construction:

A DNA sequence encoding the rat Cd80 (AAB60503.1) (Met1-Gln248) was expressed with the Fc region of human IgG1 at the C-terminus.

Source: Rat

Expression Host: HEK293 Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE.

Endotoxin:

< 1.0 EU per μg protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: lle 39

Molecular Mass:

The recombinant rat Cd80 consists 451 amino acids and predicts a molecular mass of 51 kDa.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at $-20\,^{\circ}\mathrm{C}$ to $-80\,^{\circ}\mathrm{C}$ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

References

1.Greenfield EA, *et al.* (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418. 2.Zang X, *et al.* (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9. 3.Mir MA, *et al.* (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288
■ Tel:+86-400-890-9989
■ http://www.sinobiological.com